Introduction {#s1}
============

Ovarian cancer is the most lethal gynaecological cancer, and the fifth leading cause of cancer-related death among women in the Western World [@pone.0099687-Anttonen1]. The five-year relative survival rate for women with ovarian cancer is only around 40% [@pone.0099687-Anttonen1]. Ovarian cancers are heterogeneous tumors which exhibit distinct morphological characteristics, genetic mutations and origins. There are three major types of ovarian cancer - epithelial, germ cell and sex cord stromal tumors. Ovarian germ cell tumors and sex cord stromal tumors comprise 10% of ovarian cancers, and are derived from primitive ovarian germ cells or mesenchymal cells in the sex-cord derived tissue of the ovary, respectively [@pone.0099687-Jemal1]. EOCs account for more than 90% of ovarian malignancies. Based on histology EOCs are classified into four main subtypes (serous, mucinous, endometroid and clear cell carcinomas) with over 70% of the cases diagnosed as serous carcinomas (SCs) [@pone.0099687-Ricciardelli1].

Alterations of the epigenetic landscape such as global DNA hypomethylation and gene specific DNA hypermethylation are frequently reported in cancer cells [@pone.0099687-Feinberg1]. Global DNA hypomethylation largely affects the intergenic and intronic regions of the genome, especially repeat sequences and transposable elements (TEs), which account for about 55% of the human genome [@pone.0099687-Lander1], including 17% *L1* repeats [@pone.0099687-Cordaux1]. In somatic cells, DNA methylation of TEs is crucial to prevent their expression which can jeopardise integrity of the genome. During germ cell development, there is a transient period of global DNA hypomethylation which results in temporary activation of TEs [@pone.0099687-Smallwood1].

The piRNA pathway is evolutionarily highly conserved in metazoa and consists of 21--26 nt piRNAs which bind PIWI proteins to mediate posttranslational control of TE expression and play a role in epigenetic changes (such as DNA methylation) via interaction with other proteins (such as MAEL or HP1) [@pone.0099687-Aravin1], [@pone.0099687-Sarot1]. In mammals there are several *Piwi like* (*Piwil*) genes (three in mice, four in humans). Expression of *Piwil* genes and piRNA pathway associated genes has been demonstrated at various stages of germ cell development in particular in testis. *Piwil1* (*Miwi*) has previously been identified as a gene exclusively expressed in mouse testis and essential for spermatogenesis [@pone.0099687-Deng1]. More recently expression of *Piwil1* has also been demonstrated in mouse and human ovary [@pone.0099687-Lim1]. Mutation of *Piwil2*, *Piwil4* and *Mael* in mouse leads to similar phenotypes including elimination of TE DNA methylation and male sterility [@pone.0099687-Aravin1]. There is now growing evidence of piRNA activity also in the mammalian ovary, however knock out experiments of piRNA pathway gene in mice so far has only led to male sterility [@pone.0099687-KuramochiMiyagawa1]--[@pone.0099687-Aravin2].

There is mounting evidence of piRNA pathway activity in various cancers. Expression of *PIWIL1* and *PIWIL2* has been found in a wide range of human cancers such as stomach, breast, gastrointestinal tract and endometrium [@pone.0099687-Qiao1]--[@pone.0099687-Lee1] and recently also in ovarian carcinoma [@pone.0099687-Chen1]. Increased expression of *PIWIL1* is associated with enhanced tumor growth [@pone.0099687-Janic1] increased tumor grades [@pone.0099687-Sun1], poor diagnostic outcomes [@pone.0099687-Grochola1] and mortality [@pone.0099687-Taubert1]. *PIWIL2* is widely expressed in early-stage breast and cervical cancers and pre-cancerous stem cells involved in tumorigenesis [@pone.0099687-Lee1]. The expression pattern of *PIWIL3* and *4* has only been studied in colon cancers [@pone.0099687-Li1]. *Maelstrom* (*MAEL*) is a known testis cancer gene [@pone.0099687-Xiao1].

Our finding of expression in ovarian somatic cells [@pone.0099687-Lim1] together with decreased DNA methylation at *L1* promoter region associated with the progression of cervical and uterus cancers [@pone.0099687-Shuangshoti1] and poor prognosis in ovarian carcinomas [@pone.0099687-Iramaneerat1] led us to investigate whether piRNA pathway genes could play a role in EOCs. In this study, we investigated the expression of *PIWIL1*--*4* and *MAEL* in 25 EOC, 19 benign tumor samples, and 8 normal ovarian tissues. We found significantly elevated expression of *PIWIL1* and *MAEL* in EOC compared to benign and normal ovarian tissues. However, *PIWIL1* transcripts in EOC may not be functional due to deletions identified in the PIWI domain of this transcript. Furthermore, overexpression of *PIWIL1* and *MAEL* suggests a role of these genes in reducing ovarian cancer cells invasiveness *in vitro*.

Materials and Methods {#s2}
=====================

Tissues {#s2a}
-------

Total RNAs from human testis and pre-menopause ovarian tissues were purchased from Stratagene (USA). Malignant, benign and normal ovarian tissues ([Table 1](#pone-0099687-t001){ref-type="table"} and [Table S3](#pone.0099687.s007){ref-type="supplementary-material"}) were collected with informed written consent of the patient and approval by the Ethics Committee of the Royal Adelaide Hospital, Adelaide, South Australia.
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###### Age and cancer stage of EOC, benign tumors and normal ovaries.

![](pone.0099687.t001){#pone-0099687-t001-1}

  Tissue                    n    Median of patient age in years (range)                               Cancer stage
  ------------------------ ---- ---------------------------------------- -----------------------------------------------------------------------
  Serous carcinomas         25                60 (37--75)                 See [Table S3](#pone.0099687.s007){ref-type="supplementary-material"}
  Benign ovarian lesions    19                60 (36--88)                                                  \-
  Normal ovaries            8                 48 (44--76)                                                  \-

Cell lines {#s2b}
----------

Human ovarian cancer cell lines SKOV3 and OVCAR3 were purchased from American Type Culture Collection (ATCC, USA) while OVCAR5 was obtained from Dr. Thomas Hamilton (Fox Chase Cancer Center, Philadelphia, PA) Johnson et al Cancer Res 57: 850--856 1997. Cell lines were maintained in RPMI 1640 medium supplemented with L-glutamine (2 mM), Penicillin-streptomycin (100 U/ml, 100µg/ml) (Sigma). SKOV3 and OVCAR3 cells were supplemented with 5% FBS (Invitrogen) whilst OVCAR5 cells were supplemented with 10% FBS and 7.5 µg/ml insulin. All cell lines were maintained at 37°C in a humid chamber with 5% CO~2~.

RNA isolation and cDNA synthesis {#s2c}
--------------------------------

RNA was isolated from tissues and cell lines using TRIzol reagent (Invitrogen) following the manufacturer\'s instructions. RNA was resuspended in nuclease free water, and stored at -80°C. RNA was treated with DNase I (New England Biolabs) before reverse transcription. 1µg of RNA was used to obtain cDNA using the Super Script III First-strand Synthesis System (Invitrogen) following the manufacturer's protocol. Briefly, RNA was incubated with 1µl of 50 µM oligo(dT)~20~ and 1µl of 10 mM dNTPs for 10 mins at 65°C. After incubation, 4µl of 5x RT buffer, 2µl of dithiothreitol (DTT, 0.1 M), 1µl of RNaseOUT (40 U/μl) and 1µl of Super Script III RT enzyme (200 U/μl) were added and incubated for 50 mins at 50°C. The reaction was terminated at 85°C for 5 mins. cDNAs were stored at −20°C.

Gene expression analyses {#s2d}
------------------------

RT-PCR was performed to determine the level of mRNA for the five piRNA pathway genes ([Table S1](#pone.0099687.s005){ref-type="supplementary-material"}) and beta actin (*ACTB*) in 52 patient samples and 3 ovarian cancer cell lines. Each 25µl reaction contained 200 ng of cDNA, 5µl of 5x Go Taq Green Master Mix (Promega), 1µl of 5 mM dNTP solution (Roche), 0.5µl of each primer (20 pmol/μl) and 0.5µl Taq DNA polymerase. The PCR conditions were the same for all genes, except the annealing temperature ([Table S1](#pone.0099687.s005){ref-type="supplementary-material"}), and were as follows: initial denaturation at 95°C for 2 mins, 95°C for 30 secs, annealing at gene specific temperature for 30 secs ([Table S1](#pone.0099687.s005){ref-type="supplementary-material"}), extension at 72 °C for 1 min, 32 cycles. PCR of *ACTB* control was performed with 27 cycles, followed by 5 mins of final extension at 72 °C. The PCR products were visualized on a 1.5% agarose gel stained with ethidium bromide. Band intensity was measured (Quantity One program, Version 4, Bio-Rad), and the relative intensity of each gene was normalized to that of *ACTB*. PCR products were confirmed by sequencing (Big Dye Terminator v3.1 cycle sequencing kit, Applied Biosystems). RT--PCR was performed in triplicate for each primer pair.

Statistical analyses of gene expression {#s2e}
---------------------------------------

Data are presented as median relative expression (first quartile to third quartile). The transcript level of each gene was normalized against *ACTB*. Kolmogorov-Smirnov and Shapiro-Wilk tests suggested that the expression level of each gene from all of the 52 samples is not normally distributed. Thus, a Kruskal-Wallis test, which uses a non-parametric method, was used to compare the gene expression from malignant, benign and normal groups. The Spearman\'s correlation test was performed to investigate the correlation between a patient\'s age and consequent gene expression. R-value closer to 1 indicates a stronger positive correlation, whereas an R-value closer to -1 shows a stronger negative correlation. In the Kruskal-Wallis and Spearman\'s tests, a P-value of \<0.05 was considered statistically significant.

RNA *in situ* hybridization {#s2f}
---------------------------

Probes were labelled with digoxigenin-11-UTP (Roche Diagnostics) according to the manufacturer\'s protocol. Formalin-fixed paraffin-embedded tissue sections were deparaffinised in xylene and subsequently washed in graded ethanol. All solutions were prepared in diethylpyrocarbonate (DEPC)-treated H~2~O to inactivate RNase activity. mRNA-bound nucleoproteins were removed by proteinase K incubation (1.2µg/ml) (Roche Diagnostics) for 30 mins at 37 °C. Slides were washed with 1x PBS and acetylated (1 M triethanolamin/0.178% HCl/0.25% acetic anhydride). Slides were prehybridised at 65°C for 2 hrs with prehybridization buffer (50% deionized formamide/2x SSC/1x Denhardt\'s solution/0.005 M phosphate buffer/10% dextran sulphate/1 mg/ml yeast total RNA/1 mg/ml salmon sperm DNA) and hybridised with about 200 ng of cRNA probe in prehybridization buffer overnight at 50°C in a humid chamber. Slides were washed in 2x SSC, 1x SSC, 0.5x SSC and 0.1x SSC for 15 mins each at 50°C. To remove unbound cRNA probes, the tissue was subjected to RNase A (150µg/ml) digestion for 30 mins at 37°C. Specifically bound cRNA probes were detected using an anti-DIG antibody coupled to alkaline phosphatase with nitrobluetetrazolium chloride/X-phosphate-5-bromo-4-chloro-3-indolylphosphate (NBT/BCIP) (Roche Diagnostics) as chromogenic substrate.

Cloning and construct preparation for invasion analyses {#s2g}
-------------------------------------------------------

The *MAEL* (CCDS1257) and *PIWIL1* (CCDS9268) cDNA sequences were obtained from the NCBI CCDS database. Full-length cDNA sequence was amplified using the Expand High Fidelity PCR system (Roche) according to the manufacturer\'s protocol and cloned into a pcDNA3.1 mammalian expression vector. Plasmid DNAs including pcDNA 3.1 (Invitrogen) or pEGFP-N1 empty vectors (Clontech) were transfected into SKOV3 cells using Lipofectamine LTX (Invitrogen) following the manufacturer\'s instruction. SKOV3 cells were selected due to their endogenous *L1* expression levels and the fact that they showed no piRNA pathway gene expression ([Fig. 1C](#pone-0099687-g001){ref-type="fig"}). For each transfection, 8×10^4^ SKOV3 cells were seeded onto a 24-well plate 14 hrs before transfection and were cultured in RPMI 1640/5% FBS without Penicillin-streptomycin. Plasmid DNA (500 ng) was diluted in 100µl of Opti-MEM medium (Invitrogen) and incubated with 0.5µl Plus reagent (Invitrogen) and 2µl Lipofectamine LTX (Invitrogen) for 30 mins before being added into each well. After 6 hrs, the cell culture medium was replaced with new RPMI 1640/5% FBS medium and cells were incubated for 24 hrs at 37°C, 5% CO~2~ before harvesting for *in vitro* invasion analyses. The transfection of pEGFP-N1 empty vectors into SKOV3 cells allowed the transfection efficiency to be measured, as successfully transfected cells expressed the GFP protein. The pEGFP-N1 vector was subjected to the same growth and transfection conditions as outlined above, to determine the transfection efficiency which was approximately 70% after 24 hrs.

![piRNA pathway gene expression in human normal ovaries and ovarian cancers.\
RT-PCR analyses of *PIWIL1-4* and *MAEL* expression in (A) malignant EOC, benign ovarian cancers (B) normal ovaries and (C) ovarian cancer cell lines. This is a representation of 4 out of 25 malignant EOC and 19 benign ovarian cancer tissues. Increased expression of *PIWIL1, 2, 4* and *MAEL*, but not *PIWIL3*, are found in malignant cancers compared to benign tumors. All normal ovaries show *PIWIL2* and *PIWIL4* expression but only some have *PIWIL1, 3* and *MAEL* expression. No endogenous *PIWIL1, 2, 4* and *MAEL* expression is detected in OVCAR3 and SKOV3 cells. Ova\* indicates tissue from a 20-year old pre-menopausal ovary while other ovaries are from individuals aged 44--76 years old.](pone.0099687.g001){#pone-0099687-g001}

*In vitro* invasion analyses with xCelligence {#s2h}
---------------------------------------------

Cell invasion was tested with real-time invasion assay monitoring using CIM devices and the xCelligence DP system (Roche Diagnostics) [@pone.0099687-Xi1]. Briefly, 4 hrs before the invasion assay, a CIM plate (Roche) was coated with 1∶20 diluted Growth factor reduced Matrigel basement membrane matrix (∼450µg/ml) (BD Biosciences). Then 40,000 cells, untransfected or transfected with empty vector (Ev) or *MAEL* or *PIWIL1* vectors, were seeded into each coated well. Cell activity was followed over a time period of 72 hrs by measuring the impedance signal in the CIM plate. The cell activity was recorded every minute in the first 12 hrs and every 5 mins for the following 12 hrs. Then from 24 hrs onwards until the end of the experiment, cell activity was recorded every 30 mins. In each CIM plate, triplicates of each group were performed to obtain the mean and standard deviation. The experiment was repeated three times.

*PIWIL1* transcript sequencing {#s2i}
------------------------------

The PIWI domain of *PIWIL1* transcript was PCR amplified and products of different size were cloned into pGEM-T Easy vector (Promega). A total of 30 positive colonies from different PCR bands were selected from each ligation reaction and plasmid DNAs were purified using standard alkaline lysis methods (Qiagen) [@pone.0099687-Wolf1]. 200 ng of plasmid DNA were sequenced (Big Dye Terminator v3.1 Cycle Sequencing Kit, Applied Biosystems) using SP6 and T7 universal primers.

Results {#s3}
=======

Expression of piRNA pathway genes is increased in malignant EOC compared to benign tumors or normal ovarian tissues {#s3a}
-------------------------------------------------------------------------------------------------------------------

piRNA pathway genes are consistently expressed in the mammalian ovary [@pone.0099687-Lim1]. In order to investigate a possible role of this pathway in EOC, we performed semi-quantitative RT-PCR to investigate the expression of *PIWIL1*, *PIWIL2*, *PIWIL3*, *PIWIL4* and *MAEL* in advanced stage serous EOC (n = 25), benign ovarian tumors (n = 19) and normal ovarian tissue (n = 8) ([Table 1](#pone-0099687-t001){ref-type="table"}, [Table S3](#pone.0099687.s007){ref-type="supplementary-material"} and [Fig. 1A, B](#pone-0099687-g001){ref-type="fig"}). Semi quantitative analysis revealed that the relative expression levels of *PIWIL1* and *MAEL* were significantly higher in malignant EOC compared to benign and normal tissues ([Fig. 2A, B](#pone-0099687-g002){ref-type="fig"}). The relative expression levels of *PIWIL2* and *PIWIL4* in malignant groups were not significantly different to that in benign or normal ovarian tissues ([Fig. 2C, D](#pone-0099687-g002){ref-type="fig"}). However, the expression of *PIWIL2* and *PIWIL4* are significantly lower in benign tumors compared to normal ovarian tissue, suggesting an alteration of gene expression during the progression of EOC. The relative expression of *PIWIL3* is different to other *PIWIL* genes such that the expression of this gene is significantly higher in the normal ovary when compared to both malignant and benign tissues ([Fig. 2E](#pone-0099687-g002){ref-type="fig"}). Furthermore, the relative expression of *PIWIL3* in normal ovary is positively correlated with patient age in the normal ovary tissues (n = 8) (r = 0.750, P = 0.05) ([Table 2](#pone-0099687-t002){ref-type="table"}). In contrast to *PIWIL3*, *PIWIL1* expression is negatively correlated with the age of patients (r = −0.737, P = 0.037). *PIWIL1* is expressed in growing follicles in pre-menopausal ovaries, but in this study half of the ovaries tested were from women less than 50 years old and likely to be premenopausal.

![Box plot representing the expression of piRNA pathway genes in malignant EOC, benign ovarian cancer tissues and normal ovaries.\
Semi-quantitative RT-PCR analysis of mRNA expression (relative to *ACTB*) of (A) *PIWIL1*, (B) *MAEL*, (C) *PIWIL2*, (D) *PIWIL4* and (E) *PIWIL3*. (F) P-value of each comparison group. Malignant EOC (n = 25), benign ovarian cancer tissues (n = 19) and normal ovaries (n = 8). Kruskal-Wallis Test was performed to compare the gene expression level between two groups. Filled dot indicates mean of each group. \* indicates 0.001\<P\<0.05; \*\*\* indicates P\<0.001; NS, not significant.](pone.0099687.g002){#pone-0099687-g002}

10.1371/journal.pone.0099687.t002

###### Correlation between age of patients and piRNA pathway gene expression.

![](pone.0099687.t002){#pone-0099687-t002-2}

  Genes       R-value (M, n = 25)   P-value (M, n = 25)   R-value (B, n = 19)   P-value (B, n = 19)   R-value (N, n = 8)   P-value (B, n = 19)
  ---------- --------------------- --------------------- --------------------- --------------------- -------------------- ---------------------
  *PIWIL1*          −0.376                 0.064                −0.194                 0.426                −0.737             **0.037\***
  *PIWIL2*          −0.080                 0.702                −0.442                 0.058                0.491                 0.217
  *PIWIL3*          −0.082                 0.695                 0.595              **0.009\***              0.75                 0.05
  *PIWIL4*          −0.249                 0.231                −0.376                 0.113                  0                    1.0
  *MAEL*            −0.087                 0.678                 0.251                 0.457                −0.220                0.601

Spearman\'s correlation test; M  =  malignant; B  =  benign; N  =  normal; negative value  =  negative correlation; positive value  =  positive correlation; P \<0.05 and \* indicates the correlation between the age of patients and piRNA pathway gene expression is significant. The R-value closer to ± 1 indicates the stronger correlation.

*L1* and piRNA pathway genes are over expressed in EOC cells {#s3b}
------------------------------------------------------------

To analyse the expression pattern of piRNA pathway genes and *L1* in EOC, RNA *in situ* hybridization was performed in malignant EOC (n = 5) and benign ovarian tumors (n = 2) ([Table 3](#pone-0099687-t003){ref-type="table"}, [Fig. S1](#pone.0099687.s001){ref-type="supplementary-material"}). We found strong expression of *L1* in the epithelial cells but *L1* was absent in the stromal cells in all samples ([Fig. 3A, E](#pone-0099687-g003){ref-type="fig"}). Also we noted that the expression of *L1* is variable in different patients ([Fig. 3A](#pone-0099687-g003){ref-type="fig"}). Strong expression of *PIWIL1* was found in the epithelial cells in all EOC tissues ([Fig. 3B, F](#pone-0099687-g003){ref-type="fig"}) while *MAEL* and *PIWIL2* showed strong expression in the epithelial cells and stromal cells of all EOC examined ([Fig. 3C, G and D, H](#pone-0099687-g003){ref-type="fig"} respectively).

![*L1*, *PIWIL1*, *MAEL* and *PIWIL2* are expressed in the epithelial cells of malignant EOC.\
*In situ* analysis of (A, A', E) *L1*, (B, B', F) *PIWIL1*, (C, C', G) *MAEL*, (D, D', H) *PIWIL2* in two malignant EOC (A-D from SC3 while E-H from SC2). (A'-D') Amplification images of A-D respectively. Strong expression of piRNA pathway genes and *L1* was found in the squamous-to-cuboidal like epithelial cells of both malignant EOC except *PIWIL1* which only expressed in SC2 but not SC3. *L1* has patchy expression in some EOC such that some epithelial cells seem to have stronger *L1* expression compared to others. *MAEL* and *PIWIL2* but not *PIWIL1* are also expressed in the stromal cells in both EOC. (E'-H') Negative controls with sense probe of *L1*, *PIWIL1*, *MAEL* and *PIWIL2* respectively. Ep  =  epithelial cells; S  =  stromal cells. Scale bar  =  50µm.](pone.0099687.g003){#pone-0099687-g003}

10.1371/journal.pone.0099687.t003

###### Expression trends of piRNA pathway genes and *L1* in the EOC after *in situ* hybridisation.

![](pone.0099687.t003){#pone-0099687-t003-3}

  Patient      Gene     Epithelial cells   Stromal cells
  --------- ---------- ------------------ ---------------
  SC1         *MAEL*          weak            strong
             *PIWIL2*         weak            strong
             *PIWIL1*        strong             \-
               *L1*          strong             \-
  SC2         *MAEL*          weak            strong
             *PIWIL2*         weak            strong
             *PIWIL1*         weak              \-
               *L1*          strong             \-
  SC3         *MAEL*         strong           strong
             *PIWIL2*        strong           strong
             *PIWIL1*          \-               \-
               *L1*          strong            weak
  SC4         *MAEL*           \-               \-
             *PIWIL2*        strong             \-
             *PIWIL1*        strong             \-
               *L1*          strong             \-
  SC5         *MAEL*          weak             weak
             *PIWIL2*         weak              \-
             *PIWIL1*         weak              \-
               *L1*           weak              \-
  BSC1        *MAEL*          weak             weak
             *PIWIL2*         weak             weak
             *PIWIL1*          \-               \-
               *L1*            \-               \-
  BSC2        *MAEL*          weak              \-
             *PIWIL2*         weak              \-
             *PIWIL1*          \-               \-
               *L1*            \-               \-

"-": undetectable expression.

Multiple *PIWIL1* transcript variants exist in malignant EOC {#s3c}
------------------------------------------------------------

PCR amplification of the PIWI domain from EOC cDNAs produced two distinct bands compared to cDNAs from normal testis or ovary ([Fig. 4](#pone-0099687-g004){ref-type="fig"}), suggesting the presence of multiple *PIWIL1* transcript variants in malignant EOC. PCR products from testis and malignant EOC were extracted, cloned and sequenced. Multiple alignments of clone sequences showed many changes within the PIWI domain at the nucleotide level when compared to the testis and published *PIWIL1* cDNA sequence. Single base pair changes have been identified in *PIWIL1* transcripts of malignant EOCs ([Table S2](#pone.0099687.s006){ref-type="supplementary-material"}). In addition, most of these clones have exon deletion and unspliced introns which introduce premature stop codons. Importantly a 75-nt deletion which comprised the entire exon 17 was found in most of the sequenced clones in 5 out of 28 EOC patients ([Fig. 4B](#pone-0099687-g004){ref-type="fig"}). Furthermore, some clones showed partial splicing of introns 15 and 16 ([Fig. 4B](#pone-0099687-g004){ref-type="fig"}) such that 17 bp and 20 bp from the 5′ end of intron 15 and 16, respectively, are unspliced. In order to confirm that the mutations are due to splicing, genomic DNA of tumor samples were isolated and sequenced at the corresponding region. No mutations were identified between exons 15--18 (where the splicing errors occurred) in the genomic *PIWIL1* sequence ([Fig. S2](#pone.0099687.s002){ref-type="supplementary-material"}). In order to predict if the above post-transcriptional alterations affect PIWIL1 function, sequences were translated and compared to the control (testis cDNA) and published peptide sequence (AAC97371.2). Loss of the entire exon 17 (73-nt deletion) in 11 clones introduced a premature stop codon in the PIWI domain ([Fig. S3](#pone.0099687.s003){ref-type="supplementary-material"}). Similarly, stop codons were found in clones that have unspliced introns (not shown).

![*PIWIL1* transcript variants in EOC.\
(A) *PIWIL1* expression in control tissues (human testis, normal ovary (ov) 1, 2) and EOC tissue SC1 and 2. In the positive control, a 500 bp band was amplified, but in malignant SC1, two bands were obtained. (B) cDNA multiple alignment (partial) showing that most of the clones have a deletion of exon 17 (ΔΔ3) and 3 clones have partial splicing of intron 15 and 16 (). PIWIL1_ccds: published cDNA of *PIWIL1* (CCDS9268); Testis C1: testis transcript clone 1; B1--3, B6, B9--B14, C6, C8, C9, C10--C15, D1--D10: clones with *PIWIL1* transcripts.](pone.0099687.g004){#pone-0099687-g004}

Over expression of piRNA pathway genes reduces invasiveness *in vitro* {#s3d}
----------------------------------------------------------------------

In order to investigate the possible role of piRNA pathway genes in cancer progression, full-length *PIWIL1* or *MAEL* transcripts were cloned and transfected transiently into the ovarian cancer cell line SKOV3 and assayed for invasiveness after 24 hrs of transfection. RT-PCR was performed to validate the insertion of plasmids into these cells. RT-PCR confirmed *GFP*, *PIWIL1* or *MAEL* over expression ([Fig. S4A](#pone.0099687.s004){ref-type="supplementary-material"}). Expression of *MAEL* and *PIWIL1* constructs remained high in the transfected cells 50 hr post-transfection ([Fig. S4A](#pone.0099687.s004){ref-type="supplementary-material"}). *MAEL*, *PIWIL1* and empty vector (Ev) transfected cells and untransfected SKOV3 cells were applied to the xCELLigence system to investigate their effect on cell invasiveness [@pone.0099687-Eisenberg1]. Surprisingly, the invasiveness of *MAEL* and *PIWIL1* transfected cells was lower compared to untransfected or empty vector cells ([Fig. 5](#pone-0099687-g005){ref-type="fig"}). Cell invasiveness from each group started to reach a plateau after 30 hrs, thus only cell activity of the first 30 hrs is shown. Our results suggest that overexpression of *PIWIL1* and *MAEL* have a repressive effect on SKOV3 cell invasiveness.

![Invasion assay of *MAEL* or *PIWIL1* transfected SKOV3 cells.\
*PIWIL1* and *MAEL* transfected cells have lower invasiveness compared to untransfected cells and *Ev* transfected cells. In each experiment, each group was performed in triplicate and this experiment was repeated three times. This is a combined data plot of three independent experiments for all groups. Error bars represent standard deviation. *WT* indicates untransfected SKOV3 cells; empty vector (Ev), *MAEL* and *PIWIL1* indicate cells transfected with *MAEL* or *PIWIL1* vectors. *None* indicates well without cells.](pone.0099687.g005){#pone-0099687-g005}

Discussion {#s4}
==========

The piRNA pathway is important for TE silencing, epigenetic regulation and stem cell self-renewal in a wide range of organisms [@pone.0099687-Cox1], [@pone.0099687-Siomi1]. Global DNA hypomethylation and TE derepression, such as *L1,* is a common feature of cancer genomes [@pone.0099687-RomanGomez1], [@pone.0099687-Piskareva1] in humans *PIWIL1* and *2* overexpression has been observed in tumors from various tissues [@pone.0099687-Qiao1]--[@pone.0099687-Lee1], [@pone.0099687-Sun1]--[@pone.0099687-Taubert1]. However, it is still unclear whether piRNA pathway genes are differentially expressed in ovarian cancer or have a role in ovarian tumor progression. We examined the expression of piRNA pathway genes *PIWIL1*--*4*, *MAEL* and *L1* in malignant EOC, benign tumors and normal ovary tissues, and also investigated possible roles of *PIWIL1* and *MAEL* in ovarian cancer cell lines.

Expression of *PIWIL1*--*2* has been investigated in various cancerous tissues [@pone.0099687-Qiao1]--[@pone.0099687-Lee1], [@pone.0099687-Sun1], [@pone.0099687-Taubert1], [@pone.0099687-Grochola2], but not *MAEL*, *PIWIL3* and *PIWIL4*. Although the expression of *PIWIL2* and *4* appeared high in tumor samples this was not significant, likely due to the fact that *PIWIL2* and *PIWIL4* were strongly expressed in normal ovarian tissues ([Fig. 1B](#pone-0099687-g001){ref-type="fig"}) and their expression among malignant tissues is highly variable. The expression of *PIWIL1* and *MAEL* however is significantly increased in malignant EOC when compared to benign tumors. *PIWIL1* and *MAEL,* but not *PIWIL2* and *4,* were significantly up regulated when compared to normal ovaries. In contrast to *PIWIL2* and *4* that are expressed in all normal ovarian tissues examined, the expression of *PIWIL1* and *MAEL* is found only in a subset of normal ovarian tissues from patients who were less than 50 years old. In normal ovary, *PIWIL1* and *MAEL* are expressed in the cumulus cells of growing follicles in human [@pone.0099687-Lim1]. The normal ovarian tissues tested are from individuals aged 44--76 years old, and half of these samples were derived from individuals less than 50 years old. Thus, the variable expression of *PIWIL1* and *MAEL* in the normal ovaries could be explained by the difference in abundance of growing follicles, which express piRNA pathway genes across the samples.

*MAEL* is known as a cancer/testis gene as it is expressed in testis and a number of cancer cell lines [@pone.0099687-Xiao2]. Here we identified for the first time the increased expression of *MAEL* in malignant EOC and benign ovarian tumors. Similar to PIWI, MAEL is essential to ensure proper germline stem cell differentiation in *Drosophila* and other vertebrates [@pone.0099687-Pek1]. Overexpression of piRNA pathway genes in EOC may indicate that some stem cell characteristics are present in tumor cells or that the piRNA pathway has been activated for example by activity of retrotransposons. Expression of these genes may also be a signature of the presence of ovarian cancer stem cells [@pone.0099687-Foster1].

The expression of piRNA pathway genes in normal ovary and certain types of EOC may provide a new perspective on the origin of ovarian cancer. Somatic cells of the maturing follicle may come in contact with the ovarian surface epithelium during ovulation or may be present in the inclusion cyst which is thought to play a role in the origin of epithelial ovarian cancer [@pone.0099687-Ricciardelli1] although the presence of inclusion cysts seems to not per se increase the risk of developing ovarian cancer [@pone.0099687-Sharma1]. Hypomethylation of the *L1* promoter region is correlated with increased *L1* mRNA expression, in malignant breast cancer tissues and cell lines [@pone.0099687-Alves1], [@pone.0099687-Asch1]. The expression of *PIWIL* genes and *MAEL* in both normal ovary and malignant EOC correlate with increased expression of repeat elements and raises the possibility that the piRNA pathway may have been triggered by TE expression. However, we noticed that *L1* expression was absent in earlier stage malignant tumors (n = 6) but consistently present at all stage 3c tumor samples. This provides some circumstantial evidence that the activation of piRNA pathway genes may precede *L1* expression during tumor progression. This is consistent with work in other tumors that correlate *L1* expression with cancer progression [@pone.0099687-Gualtieri1]. *Maelstrom* knock out results in decreased DNA methylation in gonads, but not in somatic tissue. In gonads this leads to a dramatic increase in transposable element expression in the germ cells [@pone.0099687-Soper1]. Our observation of *MAEL* overexpression in the absence of detectable *L1* expression in early stage tumor samples raises the possibility that non-functional *MAEL* may play a role in decreasing DNA methylation promoting subsequent *L1* expression.

Although *PIWIL1* transcript level was significantly increased in malignant EOC compared to benign and normal tissues, cloning and sequencing of these transcripts suggested that these transcripts may produce aberrant and non-functional PIWIL1 protein. Multiple mutations were found in *PIWIL1* transcripts including unspliced introns, loss of exons as well as single base pair changes. Single base pair changes maybe a result of RNA editing [@pone.0099687-Bass1]. Among thirty clones of *PIWIL1* transcripts from malignant tissues, one third of these clones have A to G (I) substitution. In addition, most of these clones have exon deletion and unspliced introns which introduced premature stop codons ([Table 2](#pone-0099687-t002){ref-type="table"}). The presence of premature stop codons suggests that although *PIWIL1* expression is high in malignant tissues, the corresponding protein (if any) maybe truncated and non-functional. Such defects in pre-mRNA splicing have been found in liver cancer and have been implicated in its progression [@pone.0099687-Berasain1].

*In situ* analyses revealed that *L1*, *PIWIL1*, *PIWIL2* and *MAEL* are strongly expressed in the epithelial cells. Surprisingly we also found evidence for *PIWIL2* and *MAEL* expression in the stromal cells in malignant EOC. It is unclear at this point if these are epithelial cells invading stromal tissue or individual stromal cells expressing these genes. Several lines of evidence have demonstrated that alteration of gene expression in stromal cells may create a microenvironment which facilitates tumor growth, playing a role in cancer progression [@pone.0099687-Stahtea1]--[@pone.0099687-Cirri1]. For example, changes of gene expression in the stromal cells surrounding colon cancer cells have been shown to produce matrix metalloproteinases (MMPs) which increase tumor invasion capacity *in vitro* and *in vivo* [@pone.0099687-Gilles1], [@pone.0099687-Okada1].

There are a number of ways in which genes associated with the piRNA pathway can play a role in genome regulation and it has been suggested that activity of these genes can have effects on methylation and expression of TEs as well as genome instability. In addition, PIWI proteins can mediate, activating or repressing effects on chromatin via interaction with heterochromatin protein 1 or polycomb group proteins. Despite this experimental evidence elucidating the role of *PIWIL1* and *MAEL* in cancer is difficult as differing effects are observed. Recent studies suggest that *PIWIL1* maybe a marker for cancer cell proliferation as it is co-expressed with KI67 [@pone.0099687-Liu1], a reliable proliferating cell marker [@pone.0099687-Brown1]. In addition, studies in a *Drosophila* brain tumor model suggested that inactivation of *Piwi* suppressed tumor growth and thus *Piwi* may promote cancer progression in this system [@pone.0099687-Janic2]. This is further supported by slowed tumor growth after knockdown of *PIWIL1* in lung cancer cell lines [@pone.0099687-Liang1]. Recently several other studies investigated the effect of *PIWI* and *MAEL* overexpression on tumor progression. Liu et al observed increased expression of the *Maelstrom* gene in hepatocellular cancer (HCC). When overexpressed, *MAEL* led to increased growth, migration and invasiveness in HCC cell lines [@pone.0099687-Liu3]. Liang et al. showed in another study, that stable overexpression of *Piwil2* in mouse embryonic fibroblasts increased proliferation and invasiveness [@pone.0099687-Shahali1]. However, in humans over expression of *PIWIL1* did not increase cell growth but caused programmed cell death in myeloid leukaemia KG1 cells, suggesting that PIWIL1 may prevent tumor development in these cells [@pone.0099687-Sharma2]. Our results in SKOV3 cells support those findings. Together this suggests that MAEL may undergo different roles depending on cell type and differentiation status. Given that these results were obtained in different cell types and tested in different assays and species it is difficult to reconcile the divergent results. One possible pathway that may shed some light on this is the AKT-GSK3b-Snail pathway. Recent work showed that *MAEL* overexpression triggers EMT via the AKT-GSK3b-SNAIL pathway. It has been suggested that activation of AKT will lead to degradation of SNAIL ultimately leading to EMT and increased invasiveness. However in SKOV3 cells *SNAIL* overexpression has been reported to increase invasiveness [@pone.0099687-Lu1]. The decrease of invasiveness after *MAEL* overexpression observed in the present study could be due to a reduction in SNAIL activity by MAEL.

Conclusions {#s5}
===========

Increasing evidence of piRNA pathway activity in various cancers raises questions about a role of this pathway in the origin and progression of these malignancies. As reported in this study, over expression of piRNA pathway genes and *L1* elements in malignant ovarian cancer suggest a role of this pathway in EOC. Expression of *PIWIL1* and *MAEL* is significantly up regulated in malignant EOC when compared to benign lesions and normal ovaries. *In situ* analyses revealed that *L1*, *PIWIL1*, *PIWIL2* and *MAEL* are strongly expressed in the cancerous cells but surprisingly *MAEL* and *PIWIL2* expression was also found in the stromal cells lining tumor tissues, suggesting a change in cell composition or identity in the tissue surrounding the cancer cells. Identification of aberrant *PIWIL1* transcript revealed that non-functional PIWIL1 proteins may be produced. In contrast to other cell systems, *in vitro* real-time invasion assay showed that over expression of piRNA pathway components such as *PIWIL1* and *MAEL* has a repressive effect on ovarian cancer cell invasiveness. Together, these results highlight the complexity in which the piRNA pathway may influence tumor progression and warrant further work to better understand the role of the piRNA pathway in the origin and progression of ovarian cancer.
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###### 

**Expression of piRNA pathway genes and** ***L1*** **in malignant EOC.** (A) *MAEL* antisense from SC2 which shows strong expression in stromal cells (+++) compared to epithelial cells which have weak expression. (B) *L1* expression in SC3. Epithelial cells have patchy strong expression of *L1* while low expression was observed in the stromal cells. +++ strong expression; + weak expression. (A'--B') Negative controls with a sense probe of *MAEL* and *L1* respectively. Scale bar = 50µm

(TIF)

###### 

Click here for additional data file.

###### 

**No mutations found in the genomic** ***PIWIL1*** **sequence in serous carcinoma 1.** SC1 gDNA was aligned with published *PIWIL1* gDNA (ENSG00000125207) sequence from exon 15 to exon 18. All exon sequences and partial intron sequences were shown. Green bar indicates 100% conservation between the aligned sequences.

(TIF)

###### 

Click here for additional data file.

###### 

***PIWIL1*** **transcript variants encoded premature stop codon.** (A) 19 clones with exon 17 (ΔΔ13) deletions, 3 clones with unspliced introns and 1 clone with a single base change resulted in the introduction of premature stop codons. PIWIL1_ccds9268: published PIWIL1 peptide sequence (AAC97371.2); Testis C1: translated testis clone 1; B1-3, B6, B9-B14, C6, C8, C9, C10-C15, D1-D10: clones with PIWIL1 translated sequence. \* inside the boxes in panel A indicates premature stop codon.

(TIF)

###### 

Click here for additional data file.

###### 

**Expression of** ***PIWIL1*** **and** ***MAEL*** **is maintained in transfected cells throughout the invasion study.** (A) RT-PCR showing the expression of *GFP*, *MAEL* and *PIWIL1* in transfected cells (left panel) at the start of invasion study (24 hrs post-transfection) and (right panel) the end of invasion study (74 hrs after transfection). The expression of *GFP, MAEL* or *PIWIL1* can only be detected in specific vector transfected cells but not empty vector transfected or wildtype cells. (B) A high number of GFP positive cells were still observed after 74 hrs of transfection. Scale bar = 10µm.

(TIF)

###### 

Click here for additional data file.

###### 

**Primers for RT-PCR and *in situ* hybridization (ISH).**

(DOCX)

###### 

Click here for additional data file.

###### 

**Nucleotide changes in PIWI domain of *PIWIL1* transcripts.**

(DOCX)

###### 

Click here for additional data file.

###### 

**Classification of the individual tumor samples used.**

(DOCX)

###### 

Click here for additional data file.
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